Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, Bergamo F, Loupakis F, Marmorino F, Berenato R, Marsico VA, Caporale M, Antoniotti C, Masi G, Salvatore L, Borelli B, Fontanini G, Lonardi S, De Braud F, Falcone A. Moretto R, et al. Among authors: loupakis f. Oncologist. 2016 Aug;21(8):988-94. doi: 10.1634/theoncologist.2016-0084. Epub 2016 Jul 5. Oncologist. 2016. PMID: 27382031 Free PMC article.
BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling.
Galuppini F, Pennelli G, Loupakis F, Lanza C, Vianello L, Sacchi D, Mescoli C, Salmaso R, Agostini M, Lonardi S, Farinati F, Rugge M, Fassan M. Galuppini F, et al. Among authors: loupakis f. Histopathology. 2017 Dec;71(6):1008-1011. doi: 10.1111/his.13315. Epub 2017 Sep 28. Histopathology. 2017. PMID: 28722262 No abstract available.
Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.
Battaglin F, Dadduzio V, Bergamo F, Manai C, Schirripa M, Lonardi S, Zagonel V, Loupakis F. Battaglin F, et al. Among authors: loupakis f. Expert Opin Biol Ther. 2017 Oct;17(10):1297-1308. doi: 10.1080/14712598.2017.1356815. Epub 2017 Jul 28. Expert Opin Biol Ther. 2017. PMID: 28752777 Review.
New perspectives for TAS-102: TASK successful?
Loupakis F, Lonardi S. Loupakis F, et al. Lancet Oncol. 2017 Sep;18(9):1139-1141. doi: 10.1016/S1470-2045(17)30574-0. Epub 2017 Jul 28. Lancet Oncol. 2017. PMID: 28760400 No abstract available.
The role of tumor angiogenesis as a therapeutic target in colorectal cancer.
Battaglin F, Puccini A, Intini R, Schirripa M, Ferro A, Bergamo F, Lonardi S, Zagonel V, Lenz HJ, Loupakis F. Battaglin F, et al. Among authors: loupakis f. Expert Rev Anticancer Ther. 2018 Mar;18(3):251-266. doi: 10.1080/14737140.2018.1428092. Epub 2018 Jan 19. Expert Rev Anticancer Ther. 2018. PMID: 29338550 Free PMC article. Review.
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients.
Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F, Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ. Schirripa M, et al. Among authors: loupakis f. PLoS One. 2018 Mar 9;13(3):e0193640. doi: 10.1371/journal.pone.0193640. eCollection 2018. PLoS One. 2018. PMID: 29522543 Free PMC article.
265 results